All lobbying filings

AVENUE SOLUTIONS

Lobbying for GENENTECH USA, INC. · Biotechnology

Filing 2nd Quarter - Report

2nd Quarter (Apr 1 - June 30) 2025 · California · House · Senate · $50,000.00 income · posted Jul 21, 2025

Official filing document

Bills named in this filing 5

HR 946
ORPHAN Cures Act
S 1862
ORPHAN Cures Act
HR 4299
Protecting Patient Access to Cancer and Complex Therapies Act
HR 1
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
HCONRES 14
Establishing the congressional budget for the United States Government for fiscal year 2025 and setting forth the appro…

Lobbying activity 2

Medicare/Medicaid

Issues related to healthcare access, quality and costs; Issues related to Medicare and Medicaid coverage and reimbursement; H.R. 946/S. 1862, ORPHAN Cures Act; Issues related to Most Favored Nation (MFN) drug pricing proposal; H.R.4299, Protecting Patient Access to Cancer and Complex Therapies Act

Health Issues

Issues related to 340b drug pricing program; Health care issues in H.R.1, To provide for reconciliation pursuant to title II of H. Con. Res. 14 (Public Law No: 119-21);

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.